Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,588.00

-25.78 (-1.60%)

, TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

19:31
02/10/19
02/10
19:31
02/10/19
19:31

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Toshiba (TOSYY; TOSBF) is preparing to slash its operating profit forecast for the year through March to between $182M-$273M, about half the projection made in November, with growing costs in sectors like energy dragging down earnings from core operations, Nikkei Asian Review's Takehiko Hama reported. 2. Saudi Arabia's minister of state for foreign affairs said the kingdom had "absolutely nothing to do" with the National Enquirer's reporting on an extramarital relationship involving Amazon (AMZN) CEO Jeff Bezos, according to Reuters. This comes after Bezos accused American Media, the Enquirer's owner, of trying to blackmail him with the threat of publishing "intimate photos" he allegedly sent to his girlfriend unless he said in public that the U.S. tabloid's reporting on him was not politically motivated, the publication noted, adding that in a blog post, he alluded to Saudi Arabia's displeasure at the Bezos-owned Washington Post's coverage of the murder of its columnist and Saudi journalist Jamal Khashoggi. 3. Alibaba (BABA) has become a proxy for China's economy and market, which is sometimes good and sometimes bad for the stock, Steven Sears wrote in this week's edition of Barron's. The link mostly benefits Alibaba, but the stock has felt some pressure over the perennial fears that China's extraordinary economic growth would slow, with the U.S.-China trade exacerbating those concerns, the publication added. But long-term investors who can take advantage of short-term uncertainty should still favor Alibaba as the stock offers a way to profit from the rise of China's middle class and the nation's incredible promise, Sears said. 4. AT&T (T) subsidiary Warner Bros' "The Lego Movie 2: The Second Part" topped the box office chart with just $35M from 4,303 theaters. The movie also struggled overseas, launching to $18.2M from 63 markets for a global bow of $53.2M. "The Lego Movie 2: The Second Part" sports a 92% Rotten Tomatoes score. 5. Wabtec (WAB), Cardinal Health (CAH), CVS Health (CVS), Medtronic (MDT), Quest Diagnostics (DGX), Boeing (BA), Estee Lauder (EL) and M&T Bank (MTB) saw positive mentions in Barron's, while AT&T was mentioned cautiously.

AMZN

Amazon.com

$1,588.00

-25.78 (-1.60%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

BABA

Alibaba

$167.36

0.39 (0.23%)

T

AT&T

$29.55

0.09 (0.31%)

WAB

Wabtec

$73.43

0.2 (0.27%)

CAH

Cardinal Health

$52.64

-1.62 (-2.99%)

CVS

CVS Health

$65.00

-0.74 (-1.13%)

MDT

Medtronic

$88.98

0.09 (0.10%)

DGX

Quest Diagnostics

$89.09

-0.63 (-0.70%)

BA

Boeing

$404.81

-0.65 (-0.16%)

EL

Estee Lauder

$154.49

2.18 (1.43%)

MTB

M&T Bank

$165.37

-1.4 (-0.84%)

  • 11

    Feb

  • 14

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

  • 06

    Mar

  • 11

    Mar

  • 18

    Mar

  • 20

    Mar

  • 18

    May

  • 28

    May

AMZN Amazon.com
$1,588.00

-25.78 (-1.60%)

02/07/19
MSCO
02/07/19
NO CHANGE
Target $99
MSCO
Overweight
PayPal acceptance growth still best of any digital wallet, says Morgan Stanley
Morgan Stanley analyst James Faucette said the most common question he has gotten for the past several weeks on PayPal (PYPL) has been, "Why is the stock underperforming so much since the beginning of 2019?" He believes PayPal's recent plateauing probably has more to do with other stocks than anything stock-specific, stating that Visa (V) and MasterCard (MA) "really have arguably had their best buying opportunities in years" and he would not be surprised to see PayPal "tread water" until those two stocks retake their respective highs. Another common thread in talks has been increasing concern that other digital wallets from Amazon (AMZN), Apple (AAPL) and others may be closing the acceptance gap, though he thinks that "speculation is flatly wrong." Dating back to March 2016, PayPal has had the fastest acceptance growth among all digital wallets, outpacing all the other wallets that he can reliably track, Faucette tells investors. He maintains an Overweight rating and $99 price target on PayPal shares.
02/05/19
JPMS
02/05/19
NO CHANGE
Target $1250
JPMS
Overweight
JPMorgan keeps Overweight on Alphabet but continues to prefer other FANGs
Alphabet's (GOOG) Q4 "continues to prove challenging on the bottom line" as the company now had a string of lighter than expected Q4's in terms of operating income and margins, JPMorgan analyst Doug Anmuth tells investors in a post-earnings research note. While the quarter is seasonally strong for advertising, it also comes with higher content costs for YouTube, more marketing spending, and a spike in low-margin hardware, says the analyst. Overall, though, Anmuth believes Alphabet continues to execute well as evidenced by both the acceleration and long-term stability in its sales growth. He maintains an Overweight rating on the shares, but prefers other FANG names Facebook (FB), Amazon (AMZN) and Netflix (NFLX) to Google. The analyst lowered his price target for the latter to $1,250 from $1,270.
02/04/19
SUSQ
02/04/19
NO CHANGE
SUSQ
Susquehanna makes case for Century Communities and Redfin to be acquired
Susquehanna analyst Jack Micenko laid out a case for why he thinks Pulte (PHM) should buy Century Communities (CCS) and why Amazon.com (AMZN) should buy Redfin (RDFN). The analyst feels Pulte is under-penetrated in the true entry-level segment of the market and Century could quickly fill the need in terms of both product type and geography. He believes Pulte could pay a roughly 40% premium to Century's current stock price and still see accretion from the deal. As for Amazon, he noted they have been more active around housing than many appreciate and he believes the data opportunity with Redfin is significant. He said Amazon could pay a roughly 60% premium to Redfin's current stock price. Micenko has a Neutral rating and $25 price target on Pulte while he does not have a rating on shares of Century Communities. Amazon is covered by analyst Shyam Patil, who has a Positive rating and $2,250 price target, and Micenko has a Positive rating and $19 price target on Redfin shares.
02/08/19
SUSQ
02/08/19
UPGRADE
Target $30
SUSQ
Positive
Air Transport Services upgraded to Positive, target raised to $31 at Susquehanna
As reported previously, Susquehanna analyst Christopher Stathoulopoulos upgraded Air Transport Services (ATSG) to Positive from Neutral. The analyst cited its extended agreement with Amazon (AZMN), which puts its growth still in the early-innings as he sees low double-digit block hour growth in 2019 as achievable. Stathoulopoulos raised his price target to $30 from $21 on Air Transport Services shares.
TOSYY Toshiba, also use TOSBF
$0.00

(0.00%)

08/15/18
COWN
08/15/18
DOWNGRADE
Target $70
COWN
Market Perform
Western Digital downgraded to Market Perform on competitive pressure at Cowen
As reported previously, Cowen analyst Karl Ackerman downgraded Western Digital (WDC) to Market Perform from Outperform as his recent supply chain field work pointed to "substantial, unabated competitive pricing tactics" by the company and Toshiba (TOSBF) to gain share of enterprise and client solid state drives. He also worries that Western Digital's efforts to scale back incremental NAND wafer adds to support pricing is not without significant risk, Ackerman tells investors. Ackerman lowered his price target to $70 from $100 on Western Digital shares, which are down about 3% to $63.20 in pre-market trading.
03/13/18
KEYB
03/13/18
NO CHANGE
KEYB
Broadcom could look at Micron next with Qualcomm blocked, says KeyBanc
President Trump's order to block Broadcom's (AVGO) proposed takeover of Qualcomm (QCOM) also likely blocks the possibility of the company trying to acquire any other player with any military/defense exposure, such as Xilinx (XLNX), KeyBanc analyst John Vinh tells investors. However, he expects Broadcom to remain acquisitive and thinks Micron (MU) could be another potential target, citing a lack of security concerns and Broadcom's previous attempts to bid for Toshiba (TOSBF), he noted. Vinh reiterates his Overweight rating and $320 price target on Broadcom, adding that he sees the executive order as a "slight positive," since it removes a near-term distraction and overhang.
07/27/18
STFL
07/27/18
NO CHANGE
Target $93
STFL
Buy
Western Digital price target lowered to $93 from $114 at Stifel
Stifel analyst Kevin Cassidy said that Western Digital's (WDC) Q1 guidance missed estimates due to NAND Flash price pressures and noted that management says they are in talks with manufacturing partner Toshiba (TOSBF) to moderate NAND supply growth. He views this discussion as a change in behavior and a positive signal that memory cycles can be dampened as companies focus on ROI rather than market share, Cassidy tells investors. Given his lowered quarterly revenue and non-GAAP EPS estimates, Cassidy cut his price target on Western Digital shares to $93, but he maintains a Buy rating on the stock.
08/15/18
08/15/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NVIDIA DOUBLE UPGRADE AHEAD OF EARNINGS: Wells Fargo analyst Aaron Rakers upgraded Nvidia (NVDA) two notches to Outperform from Underperform and raised his price target to $315 from $140, citing the company's competitive position in gaming as well as its AI / deep learning data center growth opportunities. Rakers also points to the company's new Turing GPU architecture as well as the "well-understood" investor perception of weakening in cryptocurrency-related demand. MKM SAYS LOOK BEYOND NEAR-TERM, BUY HASBRO: MKM Partners analyst Eric Handler upgraded Hasbro (HAS) to Buy from Neutral and raised his price target to $115 from $92 as he contends investors should look beyond the 2018 industry issues and anticipate a "material fundamental recovery" in the next two years thanks to the company's large toy line additions and expected margin expansion. WESTERN DIGITAL CUT TO PERFORM: Cowen analyst Karl Ackerman downgraded Western Digital (WDC) to Market Perform from Outperform as his recent supply chain field work pointed to "substantial, unabated competitive pricing tactics" by the company and Toshiba (TOSBF) to gain share of enterprise and client solid state drives. He also worries that Western Digital's efforts to scale back incremental NAND wafer adds to support pricing is not without significant risk. STIFEL SAYS BUY GW PHARMA AHEAD OF EPIDIOLEX LAUNCH: Stifel analyst Paul Matteis started GW Pharmaceuticals with a Buy rating and $181 price target, as he expects a "strong" Epidiolex launch in Dravet/Lennox Gastaut and put an 80% odds-of-success for Epidiolex in Tuberous Sclerosis complex. The analyst's epilepsy physician survey suggests broad physician and patient awareness of Epidiolex ahead of the launch, believes the 2019 consensus sales estimate of $115M "seems doable" and forecasts Epidiolex will hit $1.5B in U.S. sales in 2023.
TOSBF Toshiba, also use TOSYY
$0.00

(0.00%)

10/10/18
BFIN
10/10/18
NO CHANGE
BFIN
BlueFin checks show Lumentum received increased orders from Apple
BlueFin analysts John Donovan and Steve Mullane say their firm's latest supply chain checks suggest "strong and stable" iPhone demand. While unit demand has not changed, the mix to higher storage models has increased, which should benefit Toshiba (TOSBF), Samsung (SSNLF), and Micron Technology (MU), Donovan and Mullane tell investors in a research note. Further, BlueFin's latest checks reveal Lumentum (LITE) has received increased orders recently while competitors II-VI (IIVI) and Finisar (FNSR) continue to focus on securing second-source positioning. The latest on the two latter companies is mixed, but overall "encouraging," the analysts contend. As far as the rumors that Apple is exploring internal VCSEL development, they believe this is "more of a negotiating tactic at this point." VCSEL demand "looks to be skyrocketing" and the frustration in developing a secure second-source has likely caused Apple to explore internal development, write Donovan and Mullane. They understand Apple has looked into fabs in Taiwan to see about VCSEL development but note the earliest this could materialize is 2020-2021. This is likely more of a "call to arms" by Apple for Finisar, II-VI, and Lumentum to increase production to meet the demand, "or else face the consequences."
09/07/18
BOFA
09/07/18
NO CHANGE
Target $100
BOFA
Buy
Micron still headed for record-high revenue and profit, says BofA/Merrill
BofA/Merrill analyst Simon Woo kept his Buy rating and $100 price target on Micron (MU), saying the fundamentals of the company's earnings remain solid, and the recent correction in the stock price is likely "sentiment related". The analyst notes that the company is still headed for "record-high revenue/profit", and the stalled rise in memory chip prices does not signal a market downturn. Woo further points to a "tight" supply/demand environment and does not agree with the bears' concerns around "abnormally high chip inventories among OEMs and internet companies". Instead, Woo states that his checks suggest that Samsung (SSNLF) is experiencing "limited chip production growth" while forecasting Toshiba (TOSBF) to reduce its potential CAPEX under the management control of Bain Capital.
BABA Alibaba
$167.36

0.39 (0.23%)

01/30/19
JPMS
01/30/19
NO CHANGE
JPMS
Overweight
JPMorgan more positive on Alibaba earnings growth outlook
JPMorgan analyst Alex Yao says he's turning more positive on Alibaba's earnings growth outlook following this morning's fiscal Q3 results. The analyst sees the company's advertising revenue growing to 32% year-over-year in the March quarter driven by traffic, engagement and search algorithm optimization. The acceleration of "highly profitable" ads revenue should lead to faster earnings growth, Yao tells investors in a post-earnings research note. He recommends investors own Alibaba given the resilience of its core commerce growth outlook.
01/31/19
KEYB
01/31/19
NO CHANGE
Target $210
KEYB
Overweight
Alibaba price target raised to $210 from $200 at KeyBanc
KeyBanc analyst Hans Chung raised his price target for Alibaba to $210 from $200 saying that despite slowing in the macroeconomy, the company delivered better results in its Chinese retail marketplace. The impact of transitioning to recommendation feeds appeared better than feared and he believes the transition has increased engagement and transaction conversion and will likely yield incremental growth opportunity in future when the company begins to monetize feed traffic. The analyst reiterates an Overweight rating on the shares.
01/31/19
RHCO
01/31/19
NO CHANGE
Target $200
RHCO
Buy
Alibaba price target raised to $200 from $180 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Alibaba to $200 and kept his Buy rating after its Q3 earnings beat, saying the company has executed in spite of the "increasingly challenging macro economic/political backdrop". The analyst adds that Alibaba's secular growth drivers of rising China consumption, healthy household balance sheets, and retail digitization remain intact, even though he is a bit more cautious about the macro uncertainty, regulatory tightening, and the management's "decision to postpone monetization of new recommendation feed ".
01/31/19
OPCO
01/31/19
NO CHANGE
Target $195
OPCO
Outperform
Alibaba price target raised to $195 from $185 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Alibaba to $195 from $185 on strong Q3 core commerce results. The analyst reiterates an Outperform rating on the shares.
T AT&T
$29.55

0.09 (0.31%)

01/23/19
MKMP
01/23/19
NO CHANGE
Target $7.5
MKMP
Buy
Nokia Q4 earnings should be solid, says MKM Partners
MKM Partners analyst Michael Genovese kept his Buy rating and $7.50 price target on Nokia (NOK) ahead of its Q4 results, saying that earnings should be solid with evidence of 5G contribution, even though the outlook on its potential "won't settle the debate". The analyst notes that T-Mobile's (TMUS) 5G network build demand should also yield a good Q1 outlook with added contribution coming from the accelerated 5G plans from KT (KT) and SK Telecom in South Korea. Genovese adds that the 5G debate centers around investment plans by AT&T (T) and Verizon (VZ), but his checks indicate that the former has not made any final decisions on the timing.
01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
01/29/19
01/29/19
DOWNGRADE

Hold
Adtran downgraded to Hold at Needham on margin pressure
As previously reported, Needham analyst Richard Valera downgraded Adtran to Hold from Buy, saying that while the company posted solid Q4 results, the quarter was aided "by the re- emergence of Telmex" and warns that its shift toward international business will results in "structurally lower margins" and limited earnings power. The analyst further notes that he had previously anticipated AT&T (T) and Verizon (VZ) deals as "potentially significant" North America revenue opportunities, but now sees "little confidence either of these programs will ramp substantially over the near to medium term." Valera adds that the recent bounce in Adtran stock has taken its price to within 10% of his prior target, justifying a neutral stance.
01/25/19
HSBC
01/25/19
DOWNGRADE
Target $24
HSBC
Reduce
Dish downgraded to Reduce from Hold at HSBC
HSBC analyst Sunil Rajgopal downgraded Dish (DISH) to Reduce from Hold and cut his price target on the shares to $24 from $38, advocating that investors choose "sturdy carriers" such as Verizon (VZ), T-Mobile (TMUS), AT&T (T) and Comcast (CMCSA). For 2019, Rajgopal expects more fragmentation in the content/pay-TV business as more players enter the OTT content market and he expects the pay TV base to shrink further.
WAB Wabtec
$73.43

0.2 (0.27%)

12/20/18
WBLR
12/20/18
NO CHANGE
WBLR
Wabtec selloff brings 'compelling entry point,' says William Blair
Shares of Wabtec have declined 25% so far in December, far more disproportionately than the average 11% decline experienced by its Multi-Industry peers and the 9% decline in the S&P 500, William Blair analyst Nicholas Heymann tells investors in a research note. The selloff coincides with rising investor concerns surrounding a potential trade correction in China, slowing global GDP growth, rising interest rates in the United States, and the continued impact of transit rail delivery delays on a handful of important U.K. contracts, says the analyst. Heymann, however, is unaware of any change in Wabtec's near-term fundamental outlook or of any deterioration in the external macroeconomic indicators affecting the company. As such, he believes the stock's current price, just above the 52-week low, has created a "compelling entry point for value-oriented investors." Heymann reiterates an Outperform rating on the name.
01/25/19
GDHS
01/25/19
NO CHANGE
Target $7
GDHS
Underperform
GE modification of Wabtec deal reflects 'need for cash,' says Gordon Haskett
Gordon Haskett analyst John Inch noted that Wabtec (WAB) and General Electric (GE) announced a modification to their rail merger agreement, calling it "unusual" for the terms of such a merger to be "changed in the 11th hour." The modified deal does not appear to be beneficial to GE shareholders and GE stated that the modification is to strengthen the company's balance sheet, which reinforces Inch's view that GE is "desperate for cash to pay down its debt and other liabilities as quickly as possible," he tells investors. Inch has an Underperform rating and $7 price target on GE shares.
01/28/19
GDHS
01/28/19
NO CHANGE
Target $7
GDHS
Underperform
GE could shift to GAAP accounting, causing stock drop, says Gordon Haskett
New General Electric (GE) CEO Larry Culp likely has every intention of establishing a 2019 guidance framework that the company can actually achieve, which would be welcomed by investors after years of "non-credible GE guidance, perpetual exaggerations, opaque disclosure and aggressive accounting," Gordon Haskett analyst John Inch told investors earlier in a research note titled "Move to GAAP could drive stock hit." The analyst has an Underperform rating on General Electric with a $7 price target. The stock in morning trading is down 33c to $8.83. He believes Larry Culp, in contrast with previous CEO John Flannery, is going to want to set a guidance bar that GE "can at least hit." In turn, while GE may not be able to adopt more conservative accounting while under government investigation, a move to GAAP would at least demonstrate Culp's directional willingness to abandon the "inflated and exaggerated earnings presentation practices of the past," says Inch. However, if GE were to move to GAAP accounting, its share price would move lower, driven by a lower GAAP impact on consensus, the analyst contends. Further, GE's accounting could still be viewed as aggressive under a GAAP presentation framework, adds Inch. As such, he thinks subsequent future restatements from the adoption of more conservative accounting "could readily ensue." Inch also sees risks in GE's revised deal with Wabtec deal (WAB).
10/31/18
WELS
10/31/18
NO CHANGE
Target $105
WELS
Outperform
Wabtec price target lowered to $105 from $120 at Wells Fargo
Wells Fargo analyst Allison Poliniak-Cusic lowered his price target for Wabtec to $105 from $120 due to the re-rating of the broader Industrial group. Despite shares declining 14% in the past month on general macro/tariff concerns, shares took another step down following Q3's weaker margin and cash flow performance, she notes. The analyst believes that investor concerns centered on lower margin U.K. project work impacting Transit segment margins, but thinks the company is beginning to put these issues in the rear-view and 2018 margins will likely prove to be this cycle's trough. She reiterates an Outperform rating on the shares.
CAH Cardinal Health
$52.64

-1.62 (-2.99%)

09/21/18
RBCM
09/21/18
NO CHANGE
Target $60
RBCM
Sector Perform
Cardinal Health price target raised to $60 from $56 at RBC Capital
RBC Capital analyst George Hill raised his price target on Cardinal Health to $60 on slight adjustment of his rolled-forward model related to the timing of the company's earnings. The analyst keeps his Sector Perform rating however and warns that operational issues in its Medical business will weight on the results while its brand drug business also proves to be "optimistic". Hill further contends that Cardinal Health's brand drug pricing increase may come in below expectations, lowering FY19 EPS view to $4.79 from $4.87 which is below its current guidance range of $4.90-$5.15.
11/16/18
LEER
11/16/18
DOWNGRADE
LEER
Market Perform
Cardinal Health downgraded to Market Perform from Outperform at Leerink
11/16/18
11/16/18
DOWNGRADE
Target $55

Market Perform
Cardinal Health downgraded to Market Perform from Outperform at Leerink
Leerink analyst David Larsen downgraded Cardinal Health to Market Perform from Outperform and lowered his price target to $55 from $60. In a research note to investors, Larsen says that a recent MEDACorp survey shows that the level of distributor RFP activity may be increasing, which could lead to more pricing pressure, and that survey data shows that a significant portion of Cardinal clients do not view Cardinal as being the most competitively priced. In addition, Larsen believes that Cardinal is heavily dependent on January price increases which may disappoint, the company's Medical Division continues to face major persistent challenges from Cordis, and the core Medical business itself also seems to have slowed.
01/17/19
UBSW
01/17/19
INITIATION
Target $51
UBSW
Neutral
Cardinal Health initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Cardinal Health with a Neutral rating and $51 price target.
CVS CVS Health
$65.00

-0.74 (-1.13%)

02/07/19
MSCO
02/07/19
NO CHANGE
Target $100
MSCO
Overweight
CVS shares could rise 4%-9% on 'good enough' guidance, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser noted that CVS Health will provide guidance on February 20 for the first time since completing the Aetna transaction and he puts 60% odds on initial FY19 EPS guidance of $7.00-$7.30. While such an outlook would be below the current consensus of $7.44, bears are concerned guidance could be below $7 and such an outlook would be seen as "good enough" to drive the stock up 4%-9%, Goldwasser tells investors. If initial 2019 EPS guidance is below $7.00, which is a scenario he gives a 30% probability, the stock could be down 11%. If the initial 2019 EPS guidance range has a midpoint above $7.40, which Goldwasser assigns only 10% odds of happening, the stock could be up 10%, the analyst said. He keeps an Overweight rating and $100 price target on CVS shares ahead of the company's December quarter earnings report.
01/28/19
CLVD
01/28/19
NO CHANGE
CLVD
CVS Health likely lost Coretrust contrac, says Cleveland Research
Cleveland Research said it is likely CVS Health lost the Coretrst contract to OptumRx, on top of the loss of BCBS of South Carolina to OptumRx.
01/31/19
MSCO
01/31/19
NO CHANGE
Target $391
MSCO
Overweight
Anthem price target raised to $391 from $372 at Morgan Stanley
Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating.
01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.
MDT Medtronic
$88.98

0.09 (0.10%)

02/04/19
PIPR
02/04/19
NO CHANGE
PIPR
Overweight
Piper says UnitedHealth updated policy won't have real impact on Tandem revenue
Piper Jaffray analyst JP McKim said some will interpret UnitedHealth's (UNH) recently updated insulin pump policy, which expands Medtronic's (MDT) preferential agreement to patients age 7 and older, to mean that Tandem Diabetes (TNDM) "is farther away from getting back into good graces" with the insurer. However, while he understands that logic, McKim said he cannot know for sure either way and he thinks it won't have any real impact on Tandem's revenues. McKim, who keeps an Overweight rating on Tandem Diabetes shares, added that "patients and physicians hate this agreement as everyone wants open options for patients."
01/07/19
JPMS
01/07/19
NO CHANGE
JPMS
Overweight
Medtronic early view for below trend reported EPS growth in FY20, says JPMorgan
JPMorgan analyst Robbie Marcus noted that Medtronic CFO Karen Parkhill discussed expectations for the back half of FY19 and high level views on FY20 at the firm's healthcare conference. For FY19, the company is now expecting organic growth closer to the middle of its 5.0-5.5% range, driven by softness in CVG, said Marcus. The CFO said headwinds from higher tax rates and foreign exchange could push reported EPS growth below the company's long-range target of 8%, but expressed confidence in its ability to still hit its 4% guidance floor, adding that softer reported EPS growth in FY20 should set up FY21 for above trend reported EPS growth, according to Marcus. He maintains an Overweight rating on Medtronic shares, which are down nearly 5% to $83.92 in afternoon trading.
01/15/19
BTIG
01/15/19
UPGRADE
Target $100
BTIG
Buy
Medtronic upgraded to Buy from Neutral at BTIG
BTIG analyst Sean Lavin upgraded Medtronic to Buy with a price target of $100, saying the recent sell-off in the stock presents an attractive entry point on a "compelling relative valuation". The analyst notes that the company's recent beats have been impressive, but he had been concerned over the difficult expected comps for the second half of the year. Lavin adds that with the "new CVG concerns and cautionary language around tax proposals", Medtronic stock has become especially attractive, especially given his expectation of "results in upcoming quarters, paclitaxel concerns easing, tax changes not materializing, and enthusiasm around low-risk expansion".
01/08/19
LEHM
01/08/19
NO CHANGE
Target $104
LEHM
Overweight
Medtronic price target lowered to $104 from $113 at Barclays
Barclays analyst Kristen Stewart lowered her price target for Medtronic to $104 saying management yesterday made some cautious commentary on the near-term sales outlook and recent tax regulation proposals. It seems that Medtronic "is a bit two steps forward and now one step back," Stewart tells investors in a research note. The analyst, who is not surprised by the 6.5% selloff yesterday, keeps an Overweight rating on the shares, citing valuation and Medtronic's longer term growth prospects with its pipeline.
DGX Quest Diagnostics
$89.09

-0.63 (-0.70%)

01/31/19
ARGS
01/31/19
DOWNGRADE
ARGS
Hold
Quest Diagnostics downgraded to Hold from Buy at Argus
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
Quest Diagnostics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Quest Diagnostics to Underperform from Neutral and lowered its price target to $72 from $93. Analyst Derik de Bruin said Quest is operating in a price deflationary environment due to headwinds from the Protecting Access to Medicare Act and contract openings for lab contracts. de Bruin views the current environment for labs as unlike prior periods and said recent soft volume trends may be a prelude to deeper structural issues not fully understood by the market
01/31/19
ARGS
01/31/19
DOWNGRADE
ARGS
Hold
Quest Diagnostics downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Quest Diagnostics to Hold, citing the latest downward revision in FY18 guidance by its management due to increased reserves and soft volume trends. The analyst adds that the company continues to face pressure from lower Medicaid payment rates for clinical laboratory tests, adding that its current challenges and reduced guidance warrant caution. Hellweg notes that he would consider returning the rating to Buy if Quest Diagnostics can improve its fundamental performance.
01/17/19
UBSW
01/17/19
INITIATION
Target $90
UBSW
Neutral
Quest Diagnostics initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Quest Diagnostics with a Neutral rating and $90 price target.
BA Boeing
$404.81

-0.65 (-0.16%)

02/04/19
JEFF
02/04/19
NO CHANGE
Target $448
JEFF
Buy
Boeing price target raised to $448 from $394 at Jefferies
Jefferies analyst Sheila Kahyaoglu raised her price target for Boeing to $448 saying the company's Q4 results highlighted many of the trends that support her investment thesis, including productivity-driven earnings and growing free cash flow driving capital deployment optionality. The analyst keeps a Buy rating on Boeing.
01/31/19
FBCO
01/31/19
NO CHANGE
Target $440
FBCO
Outperform
Boeing price target raised to $440 from $434 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Boeing to $440 from $434 and reiterated an Outperform rating on the shares. With visibility well into the 2020s, the analyst believes Boeing could among the more resilient industrials be in a global slowdown.
02/05/19
BERN
02/05/19
NO CHANGE
Target $459
BERN
Outperform
Boeing price target raised to $459 from $435 at Bernstein
Bernstein analyst Douglas Harned raised his price target for Boeing to $459 from $435 after "strong" margins and cash for 2018 and 2019 guidance. The analyst notes that he heard investor concerns about cash from challenges on the 737MAX, but that was not the case. Boeing is Harned's top pick in U.S. Aerospace & Defense. He reiterates an Outperform rating on the shares.
02/04/19
FBCO
02/04/19
NO CHANGE
Target $103
FBCO
Outperform
Spirit AeroSystems price target raised to $103 from $96 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Spirit AeroSystems (SPR) to $103 from $96 and reiterated an Outperform rating on the shares. With a challenging 2018 behind the company, the analyst thinks there is smoother sailing ahead on the upcoming production ramps. With visibility and margins improving, Spingarn continues to see upward momentum for the shares as ramping defense platforms should continue to provide a top-line lift even if commercial production rates stabilize in 2020, efficiency initiatives should support margins despite pricing step-downs, the most recent MOA with Boeing (BA) removes uncertainty and suspends advance repayments on the 787, while management plans to maintain its shareholder-friendly capital deployment once the pending Asco acquisition closes.
EL Estee Lauder
$154.49

2.18 (1.43%)

02/06/19
FBCO
02/06/19
NO CHANGE
Target $175
FBCO
Outperform
Estee Lauder price target raised to $175 from $165 at Credit Suisse
Credit Suisse analyst Michael Binetti raised his price target for Estee Lauder to $175 from $165 as the company shakes off global growth concerns with strong Q2 results. The analyst reiterates an Outperform rating on the shares.
02/06/19
WELS
02/06/19
NO CHANGE
Target $142
WELS
Market Perform
Estee Lauder price target raised to $142 from $135 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised his price target for Estee Lauder to $142 from $135 saying that while he expected the company's growth to be strong in Q2, results were much better than expected. The analyst reiterates a Market Perform rating on the shares.
02/06/19
02/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Neutral from Buy at Guggenheim with the firm citing balanced risk/reward. 2. Arlo Technologies (ARLO) downgraded to Underperform from Neutral at BofA/Merrill and to Market Perform from Outperform at Cowen. 3. Celanese (CE) downgraded to Market Perform from Outperform at Cowen with analyst Charles Neivert saying recent subtle changes in industry fundamentals and the macro outlook have made him more cautious. 4. Estee Lauder (EL) downgraded to Hold from Buy at Berenberg with analyst Rosie Edwards saying that while the company's Q2 results were "strong across the board," she expects top-line growth to moderate, due mainly to skincare and Asia-Pacific. 5. Vanda Pharmaceuticals (VNDA) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Charles Duncan saying the company's complaint against the FDA reduces visibility on development timelines for tradipitant in gastroparesis, perhaps even pruritus, and may also affect Hetlioz label expansion efforts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/19
DBAB
02/06/19
NO CHANGE
Target $167
DBAB
Buy
Estee Lauder price target raised to $167 from $157 at Deutsche Bank
Deutsche Bank analyst Steve Powers raised his price target for Estee Lauder to $167 saying the company delivered an "assertive" beat and raise quarter, characterized by "strong" organic top-line growth of 11% and encouraging commentary on China. He keeps a Buy rating on the shares.
MTB M&T Bank
$165.37

-1.4 (-0.84%)

12/12/18
KBWI
12/12/18
DOWNGRADE
KBWI
Market Perform
Keefe, wanting to own defensive banks, downgrades Comerica and KeyCorp
Keefe Bruyette analyst Brian Klock expects the narrative in 2019 to shift to "defensive banks that can grow earnings using other levers rather than depending on rates." With that in mind, the analyst downgraded both Comerica (CMA) and KeyCorp (KEY) to Market Perform from Outperform. Comerica's revenue and earnings growth are largely dependent upon future Fed funds hikes, Klock tells investors in a research note. Further, he sees risk to his revenue growth assumptions next year for KeyCorp and does not see 2019 as the year the company's price-to-earnings multiple closes the discount compared to peers. Klock's top overweight picks among the Large Regionals are Citizens Financial (CFG), M&T Bank (MTB), SunTrust (STI) and Zions Bancorp (ZION).
10/23/18
BARD
10/23/18
UPGRADE
Target $185
BARD
Outperform
M&T Bank upgraded to Outperform at Baird
As reported previously, Baird analyst David George upgraded M&T Bank to Outperform from Neutral. The analyst noted the recent share price decline due to concerns about sluggish loan growth, which largely reflects targeted run-off in the residential mortgage portfolio. The loan growth should seasonally improve in Q4, contends George, who called the bank a quality name that he believes is "on-sale." George raised his price target to $185 from $180 on M&T Bank shares.
01/08/19
UBSW
01/08/19
UPGRADE
UBSW
Neutral
M&T Bank upgraded to Neutral from Sell at UBS
01/09/19
UBSW
01/09/19
UPGRADE
Target $157
UBSW
Neutral
M&T Bank upgraded to Neutral from Sell at UBS
UBS analyst Saul Martinez upgraded M&T Bank to Neural while lowering his price target for the shares to $157 from $171. The stock's "ample" valuation de-rating has brought a balanced risk/reward profile, Martinez tells investors in a research note.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.